Tetrabenazine News and Research

RSS
Tetrabenazine is a highly selective and reversible centrally-acting dopamine depleting drug that works by inhibiting a molecule known as vesicular monoamine transporter 2 (VMAT2). Xenazine was approved by the FDA on August 15, 2008, for the treatment of chorea associated with Huntington's disease, based on the results of a double-blind, placebo-controlled, Phase 3 study that found Xenazine significantly reduced patients' chorea burden, improved global outcome scores, and was generally safe and well tolerated. Additional post-marketing preclinical studies further elucidating the safety profile of the product are being conducted. Tetrabenazine has been available in Europe for more than 30 years and in Canada since 1996.
Deutetrabenazine may help improve chorea symptoms in patients with HD

Deutetrabenazine may help improve chorea symptoms in patients with HD

Deuteration offers alternative chorea treatment for Huntington disease patients

Deuteration offers alternative chorea treatment for Huntington disease patients

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

FDA clears Omeros' OMS824 IND for treatment of Huntington's disease

FDA clears Omeros' OMS824 IND for treatment of Huntington's disease

Teva concludes Asset Transfer Agreement with NeuroSearch

Teva concludes Asset Transfer Agreement with NeuroSearch

New AAN guideline recommends several treatments for people with Huntington's chorea

New AAN guideline recommends several treatments for people with Huntington's chorea

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail reports 27% increase in first-quarter 2010 total revenues

Presentation of results from open-label extension study of Xenazine

Presentation of results from open-label extension study of Xenazine

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Huntington's disease: Latrepirdine appears well-tolerated and beneficial

Huntington's disease: Latrepirdine appears well-tolerated and beneficial

Third-quarter financial results for the year 2009 announced by Biovail

Third-quarter financial results for the year 2009 announced by Biovail

Biovail acquires worldwide rights to Tetrabenazine

Biovail acquires worldwide rights to Tetrabenazine

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Labs announces Spanish approval of Tetrabenazine

First drug for Huntington's disease approved for use in the U.S.

First drug for Huntington's disease approved for use in the U.S.